Loading...
Loading...
XBIO| Name | Value |
|---|---|
| Revenues | 510.8K |
| Cost of Revenue | 0.0K |
| Gross Profit | 510.8K |
| Operating Expense | 1,779.2K |
| Operating I/L | -1,268.4K |
| Other Income/Expense | 73.3K |
| Interest Income | 73.2K |
| Pretax | -1,195.1K |
| Income Tax Expense | 10.6K |
| Net Income/Loss | -1,195.1K |
Xenetic Biosciences, Inc. is a biopharmaceutical company specializing in the development of personalized chimeric antigen receptor T cell (CAR T) platform technology, targeting patient-specific tumor neoantigens. The company focuses on advancing cell-based therapeutics for the treatment of B-cell lymphomas by targeting the B-cell receptor on the surface of individual patient's malignant tumor cells. Additionally, it leverages its proprietary drug delivery platform, PolyXen, through collaborations with biotechnology and pharmaceutical companies, including Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC.
